6 July, 2018
The addition of two more US patents to ARANZ Medical’s portfolio of skin surface measurement products further strengthen and secure the company’s IP and product lines.
ARANZ Medical’s Silhouette solution uses innovative technology to drive better health outcomes for patients and provides considerable efficiencies over other common skin assessment solutions for clinical practice and research organizations alike.
The latest patents (9,955,910 and 10,013,527) help to secure the company’s market-leading position in automatically assessing an anatomical surface feature and securely managing information related to this.
ARANZ Medical CEO, Bruce Davey says, “Our growing portfolio of patents is testament to the unique position we hold in the area of wound and skin surface measurement. The growing awareness of the benefits of our systems, customer acceptance of our easy to use products, and the growing strength of our IP portfolio provides us with confidence to continue investing in new innovations for our product lines.”
ARANZ Medical’s Silhouette skin imaging and measuring solutions are a popular choice both for organizations undertaking clinical trials on skin and wound treatments and for healthcare providers looking to improve business and patient outcomes. In the company’s clinical trials business, more than 120 clinical trials have been conducted using Silhouette, for pre-clinical to post-market studies—the largest study to date having more than 200 imaging devices spread over sites in 13 countries. Common study indications include Diabetic Foot Ulcers, Venous Leg Ulcers, Pressure Ulcers, Epidermolysis Bullosa, as well as various dermatology conditions. More than 120,000 subject assessments have been captured and processed with Silhouette in the course of these clinical trials.
About ARANZ Medical
ARANZ Medical Limited is a global medical device company focused on commercializing innovative, proprietary medical image-capture devices and recording, reporting and analysis software. The company’s systems are primarily used in the chronic wound market, and are well-suited to clinical trials and telemedicine applications. aranzmedical.wpengine.com
CHRISTCHURCH, New Zealand, July 6th, 2018 – SOURCE: ARANZ Medical
Doc Number: 2018-00223 Rev: 1.0